ONCOLOGY SE MENAGEMENT Flashcards
WHAT IS NADIR AND WHEN DOES IT OCCUR DURING CHEMOTHERAPY
THE LOWEST POINT THAT WBC AND PLATELETS REACH
OCCURS ABOUT 7-14 DAYS AFTER CHEMO
HOW LONG DOES IT TAKE FOR WBC AND PLATELETS TO RECOVER
3-4 WEEKS POST TREATMENT
NEUTROPENIA AT WHAT ANC?
< 1000 CELLS/MM3
SEVERE NEUTROPENIA AT WHAT ANC
< 500 CELLS/MM3
WHAT ARE G-CSFs AND THEIR NAMES?
GROWTH COLONY STIMULATING FACTORS STIMULATE WBC PRODUCTION
FILGRASTIM AND PEGFILGRASTIM
WHEN ARE CSFs GIVEN AND WHY?
GIVEN PROPHYLACTICALLY AFTER CHEMO TO SHORTEN TIME A PT IS AT RISK FOR INFECTION AND REDUCE MORTALITY FROM INFECTION.
PREVENT NEUTROPENIA
G-CSF SIDE EFFECTS
BONE PAIN, FEVER, ARTHRALGIAS, MYALGIAS, RASH
WHAT IS FEBRILE NEUTROPENIA
WHEN A FEVER IS PRESENT IN A NEUTROPENIC PATIENT.
AT RISK OF DEATH FROM SEPSIS
FEBRILE NEUTROPENIA DIAGNOSIS REQUIREMENTS
ORAL TEMP > 38.3 C
ANC < 500
FEBRILE NEUTROPENIA EMPIRIC ANTIBIOTICS STARTED WHEN AND COVER WHAT?
IMMEDIATELY AFTER FEVER OCCURS
SHOULD HAVE ADEQUATED GN COVERAGE, INCLUDING PSEUDOMONAS
FEBRILE NEUTROPENIA ABX FOR LOW RISK
LOW RISK = ANC < 500 FOR ≤ 7 DAYS AND NO COMORBIDITIES
ORAL ANTI-PSUDOMONAL: (CIPRO OR LEVO) + (AUGMENTIN OR CLINDAMYCIN)
FEBRILE NEUTROPENIA ABX FOR HIGH RISK
HIGH RISK = ANC < 100 FOR ≥10 DAYS AND COMORBIDITIES OR RENAL OR HEPATIC IMPAIRMENT
IV ANTI-PSEUDOMONA BETA-LACTAM (CEFEPIME, CEFTAZIDIME, MEROPENEM, IMI/CILASTATIN, PIP/TAZO)
WHAT ARE ESAs
ERYTHROPOIESIS-STIMULATING AGENTS
EPOETIN-ALFA (EPOGEN, PROCRIT) AND DARBEPOETIN ALFA (ARANESP)
STIMULATE RBC
WHEN TO GIVE ESAs
FOR PALLIATIVE ONLY
WHEN HGB < 10
RISK FACTORS FOR N&V
FEMALE
<50 YEARS
ANXIETY/DEPRESSION
DEHYDRATION
HX OF N&V (MOTION, PRIOR CHEMOS)
FOR CINV, WHEN DOES ONE ADMINISTER ANTIEMETICS
AT LEAST 30 MINUTES PRIOR TO CHEMOTHERAPY
PROVIDE TAKE-HOME ANTIEMETICS FOR BREAKTHROUGH
ACUTE CINV MANAGEMENT
ONSET WITHIN 24 HOURS AFTER CHEMO
5HT3-RA
NK1-RA
DEXAMETHASONE
OLANZAPINE
DELAYED CINV MANAGEMENT
ONSET > 24 HOURS AFTER CHEMO
NK1-RA
CORTICOSTEROIDS
PALONOSETRON
OLANZAPINE
WHICH CHEMO AGENT HAS THE HIGHEST EMETIC RISK POTENTIAL
CISPLATIN